Balancing the TAF vs. TDF Equation: Adding Weight Gain and Lipid Levels to the Mix

Persons with HIV who switched to tenofovir alafenamide–containing regimens had greater weight gain and higher lipid levels than those who remained on tenofovir disoproxil fumarate.

The contribution of different antiretroviral agents to weight gain in persons with HIV (PWH) is currently debated. In this retrospective study using data from the Swiss National HIV Cohort, researchers evaluated the relative contributions of tenofovir alafenamide (TAF) versus tenofovir disoproxil fumarate (TDF) to changes in weight among 4375 participants on stable TDF-containing antiretroviral therapy for ≥6 months who then either switched from TDF to TAF without additional regimen changes (79.6%) or continued their TDF-containing regimen (20.4%).

At 18 months, weight gain was significantly greater (by 1.1 kg) in those who switched to TAF than who stayed on TDF, particularly in women of African (1.5 kg) and non-African (1.4 kg) origin. Havi…

Reviewing Author

Wendy S. Armstrong, MD

Disclosures

Consultant/Advisory BoardNIH Therapeutics and Prevention Data Safety Monitoring Board

Leadership Positions in Professional SocietiesAmerican Board of Internal Medicine Infectious Diseases Subspecialty Board (member), Infectious Diseases Society of America (Vice President)

Wendy S. Armstrong, MD

Disclosures

Consultant/Advisory BoardNIH Therapeutics and Prevention Data Safety Monitoring Board

Leadership Positions in Professional SocietiesAmerican Board of Internal Medicine Infectious Diseases Subspecialty Board (member), Infectious Diseases Society of America (Vice President)

Balancing the TAF vs. TDF Equation: Adding Weight Gain and Lipid Levels to the Mix

Topics

Reviewing Author